A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

Recruiting now. Registry record last updated May 12, 2026.

Who can join: Adults 18+, have alcohol use disorder, BMI 27+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 7 months.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor Yale UniversityDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 10

What this study is for

Primary condition: Alcohol Use Disorder. Also studied in: Weight Loss, Bariatric Surgery Patients.

Full scientific study title: Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS).

Who can join

Age18 and upSexAnyBMI27 to 50

Adults 18+, have alcohol use disorder, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)
Age 18 and older
Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg/m2
Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years

Key exclusion criteria

Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening
History or presence of chronic or recurrent pancreatitis
History of malignant neoplasms within the past 5 years prior to screening
Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
Is currently using other medications for weight loss or other GLP-1 receptor agonists

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Connecticut1 site

Yale School of Medicine
New Haven, Connecticut

Follow this trial

We email you if NCT07223983 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: March 6, 2026. Expected completion: October 31, 2026. Last updated on ClinicalTrials.gov: May 12, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.